Vimarsana
Biggest News Aggregation in the World

Page 3 - Discussion Session News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Discussion Session. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Discussion Session Today - Breaking & Trending Today

Veru Announces Acceptance of Two Abstracts for Presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting - Vimarsana News

Veru Announces Acceptance of Two Abstracts for Presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Share: -- Presentation of Phase 2 trial clinical trial data from patients with AR+ER+HER2- metastatic breast cancer demonstrating that the antitumor efficacy of enobosarm, a selective androgen receptor targeting agent, treatment is dependent on the magnitude of expression of androgen receptor (AR) in breast cancer tissue -- -- Presentation of Phase 1b/2 updated clinical trial results of sabizabulin (VERU-111), an oral androgen receptor transport disruptor, in metastatic castration and androgen receptor targeting agent resistant prostate cancer -- MIAMI, May 24, 2021 (GLOBE NEWSWIRE) -- Veru...

HUTCHMED Highlights Clinical Data to be Presented at the - Vimarsana News

HUTCHMED Highlights Clinical Data to be Presented at the

Title: A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations. Lead Author Session: Abstract Number: About Savolitinib Savolitinib is an oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase which has been shown to function abnormally in many types of solid tumors promoting tumor growth, angiogenesis, and metastasis. Savolitinib has been studied in over 1,100 patients to date. In clinical studies, it has shown promising clinical efficacy i...

BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting - Vimarsana News

BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--May 19, 2021-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results and updates from its broad portfolio will be presented at the 2021 Annual Meeting of the American Society of Cancer Oncology (ASCO) being held June 4 – 8, 2021. “We are pleased to share updates from our growing clinical portfolio across solid tumors and hematologic malignancies at this year’s ASCO, including multiple novel combinations ...

Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion ... - Vimarsana News

Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion ...

More from AP

Source: apnews.com
Gamasutra - Go behind the scenes at the studio behind Mario Kart Live at GDC Showcase - Vimarsana News

Gamasutra - Go behind the scenes at the studio behind Mario Kart Live at GDC Showcase

Mario Kart hit the road---literally---with Mario Kart Live: Home Circuit, a unique hybrid of remote control cars and AR Gameplay that turned players’ Nintendo Switch devices into controllers for real toy cars. Now at GDC Showcase, you’ll get to hear more about the studio behind Mario Kart Live, as the fantastic folks from Velan Studios are giving a talk at GDC Showcase about life at their studio, and what it’s taken for them to succeed in a competitive business. And as part of our Discussion Session format, you’ll have the chance to ask Velan Studios’ developers whatever questions...